This section features all recent CSL Behring news releases. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.
Global biotherapeutics leader, CSL Behring today announced that the Australian Therapeutic Goods Administration (TGA) has approved AFSTYLA® [lonoctocog alfa].
CSL Behring marks World Hemophilia Day by donating its bleeding disorders medicines to the World Federation of Hemophilia (WFH).
CSL Behring continues legacy of support for Alpha-1 Community with Global Research Conference and Patient Congress Sponsorship.
Like the other 253 sites that comprise the Jeffrey Modell Centers Network, the North African Network will offer advanced diagnostic evaluation to patients with a suspected primary immunodeficiency, a group of over 350 disorders arising from defects in the immune system carried by the genes and characterized by recurring infections that can be persistent, debilitating, chronic and life-threatening.
Patients are the most compelling advocates for access to care, which is why CSL Behring awards Local Empowerment for Advocacy Development (LEAD) grants to support advocacy work of rare disease patient groups. These groups tackle complex legislative and public policy issues and ensure patients’ voices are heard on Capitol Hill and in statehouses across the U.S.